Viatris | VTRS - Operating Profit


Viatris reported $255.5M in Operating Profit for its fiscal quarter ending in September of 2026.





Operating Profit Change Date
Celltrion KRW 19.31B 6.4B Jun/2026
Cspc Pharmaceutical CNY 206.26M 1.02B Dec/2025
Deva Holding AS TRY 964.87M 240.32M Sep/2023
Dianthus Therapeutics USD -61.48M 14.95M Jun/2026
Divis Laboratories Ltd INR 14.24B 2.95B Sep/2026
Kangmei Pharma CNY -35.26M 24.32M Jun/2026
Knight Therapeutics CAD 6.21M 3.27M Dec/2025
Laboratorios Farma EUR 135.05M 49.84M Dec/2023
Malin Corporation EUR -1.1M 400K Dec/2024
Medical Developments International AUD -36K 444K Dec/2025
Neuren Pharmaceuticals AUD 17.01M 11.56M Dec/2025
Organigram Holdings CAD 5.33M 15.12M Jun/2026
Ovoca Bio EUR -173K 990K Dec/2025
Pharma Mar EUR 7.65M 9.06M Sep/2026
Qiagen NV USD 141.4M 24.77M Jun/2026
Sartorius EUR 179.8M 15.8M Sep/2026
Sino Biopharmaceutical CNY 5.18B 3.32B Jun/2025
Tilray USD -20.01M 9.34M Sep/2025
Viatris USD 255.5M 181.8M Sep/2026
Zealand Pharma A/S -539M 168.05M Mar/2026
Zz Pientze Pharmaceu CNY 222.81M 140.02M Sep/2026